Page last updated: 2024-12-05

mabuterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mabuterol is a selective β2-adrenergic receptor agonist, chemically similar to salbutamol (albuterol). It has been studied for its bronchodilator effects in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Mabuterol has a longer duration of action than salbutamol, making it potentially useful for long-acting bronchodilation. Studies have shown that mabuterol can effectively relax airway smooth muscle, leading to improved lung function. Its synthesis involves chemical modifications of existing β2-agonists, but specific details are not readily available in the public domain. Further research is necessary to fully understand its therapeutic potential, safety profile, and long-term effects.'

mabuterol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3995
CHEMBL ID86749
CHEBI ID135325
SCHEMBL ID82440
MeSH IDM0130104

Synonyms (39)

Synonym
CHEMBL86749
ambuterol
NCGC00181010-01
mabuterol
mabuterol [inn]
ccris 5288
benzenemethanol, 4-amino-3-chloro-alpha-(((1,1-dimethylethyl)amino)methyl)-5-(trifluoromethyl)-
mabuterolum [inn-latin]
pb 868cl
4-amino-alpha-((tert-butylamino)methyl)-3-chloro-5-(trifluoromethyl)benzyl alcohol
L013373
CHEBI:135325
1-[4-amino-3-chloro-5-(trifluoromethyl)phenyl]-2-(tert-butylamino)ethanol
56341-08-3
A831005
1-[4-amino-3-chloro-5-(trifluoromethyl)phenyl]-2-(tert-butylamino)ethanol;mabuterol
mabuterolum
r4k19w6s7q ,
unii-r4k19w6s7q
AKOS016010365
FT-0630690
mabuterol [mi]
mabuterol [who-dd]
mabuterol [mart.]
4-amino-.alpha.-((tert-butylamino)methyl)-3-chloro-5-(trifluoromethyl)benzyl alcohol
56707-24-5
SCHEMBL82440
1-(4-amino-3-chloro-5-(trifluoromethyl)phenyl)-2-(tert-butylamino)ethanol
DTXSID3048283
benzenemethanol, 4-amino-3-chloro-.alpha.-[[(1,1-dimethylethyl)amino]methyl]-5-(trifluoromethyl)-
Q6721687
AMY13636
56341-08-3 (free base)
mabuterol free base
benzenemethanol, 4-amino-3-chloro-?-[[(1,1-dimethylethyl)amino]methyl]-5-(trifluoromethyl)-; 4-amino-3-chloro-?-[[(1,1-dimethylethyl)amino]methyl]-5-(trifluoromethyl)benzenemethanol; (+/-)-mabuterol; ambuterol; pb 868cl
mabuterol 1000 microg/ml in acetonitrile
1ST1321
CS-0003199
HY-13338

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Serial plasma samples were collected and the pharmacokinetic behavior of each enantiomer in rats was characterized using a sequential achiral and chiral liquid chromatographic method."( Enantioselective pharmacokinetics of mabuterol in rats studied using sequential achiral and chiral HPLC.
Chen, H; Li, F; Liu, P; Lu, X; Qin, F, 2005
)
0.6

Compound-Compound Interactions

ExcerptReferenceRelevance
"Dispersive liquid-liquid microextraction based on solidification of floating organic drop (DLLME-SFO) was for the first time combined with field-amplified sample injection (FASI) in CE to determine four β(2)-agonists (cimbuterol, clenbuterol, mabuterol, and mapenterol) in bovine urine."( Dispersive liquid-liquid microextraction based on solidification of floating organic drop combined with field-amplified sample injection in capillary electrophoresis for the determination of beta(2)-agonists in bovine urine.
Alshana, U; Ertaş, N; Göğer, NG; Lubbad, I; Us, MF, 2013
)
0.57

Bioavailability

ExcerptReferenceRelevance
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31

Dosage Studied

Mabuterol was tested in male rats dosed with 20, 100 and weekly increasing doses of 20, 40, 60, 80 and 100 mg/kg over 7 weeks. In subacute and chronic studies in Wistar rats, mabuterl was dosed by gavage at 0, 10, 20, 30, 40 and 80 mg/ kg for 1 month.

ExcerptRelevanceReference
"-butyl-amino-ethanol hydrochloride (mabuterol) was tested in male rats dosed with 20, 100 and weekly increasing doses of 20, 40, 60, 80 and 100 mg/kg over 7 weeks."( Special toxicology--physical dependence potential, antigenicity and mutagenicity--of mabuterol.
Amemiya, K; Arika, T; Asano, T; Kudoh, M; Nakamura, M, 1984
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
(trifluoromethyl)benzenesAn organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (47.50)18.7374
1990's11 (27.50)18.2507
2000's2 (5.00)29.6817
2010's6 (15.00)24.3611
2020's2 (5.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.26 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index5.28 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (7.32%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (92.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]